United Therapeutics’ Ralinepag Cuts PAH Worsening Risk by 55%, Preps FDA NDA
United Therapeutics’ phase 3 ADVANCE OUTCOMES study of ralinepag reduced PAH clinical worsening risk by 55% and boosted clinical improvement odds by 47% in pre-treated patients. The drug was well-tolerated with no new safety signals, and the company plans an FDA NDA submission by H2 2026.
1. Trial Results
Phase 3 ADVANCE OUTCOMES study showed ralinepag achieved a 55% reduction in risk of clinical worsening events in PAH patients and increased odds of clinical improvement by 47% among predominantly pre-treated participants. No new safety signals were observed, supporting its tolerability profile.
2. Regulatory Path
United Therapeutics plans to submit a New Drug Application for ralinepag to the FDA by the second half of 2026 based on these positive efficacy and safety outcomes. Results are slated for presentation at an upcoming international conference to reinforce clinical validation.
3. Market Reaction and Analyst Outlook
Shares of United Therapeutics rose following the trial announcement, outperforming broader market declines. Analysts at HC Wainwright, TD Cowen and Oppenheimer have raised price targets up to $600, reflecting heightened confidence in ralinepag’s commercial potential.